{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:39:57Z","timestamp":1786365597812,"version":"build-2736575974"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2003,10,1]],"date-time":"2003-10-01T00:00:00Z","timestamp":1064966400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2003,10]]},"DOI":"10.1007\/s11906-003-0087-9","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T03:13:07Z","timestamp":1180062787000},"page":"408-417","source":"Crossref","is-referenced-by-count":56,"title":["RAAS escape: A real clinical entity that may be important in the progression of cardiovascular and renal disease"],"prefix":"10.1007","volume":"5","author":[{"given":"Jay","family":"Lakkis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei X.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"87_CR1","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1161\/hy1201.101214","volume":"38","author":"N Basso","year":"2001","unstructured":"Basso N, Terragno NA: History about the discovery of the renin-angiotensin system. Hypertension 2001, 38:1246\u20131249.","journal-title":"Hypertension"},{"key":"87_CR2","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1161\/01.HYP.34.6.1265","volume":"34","author":"A Rohrwasser","year":"1999","unstructured":"Rohrwasser A, Morgan T, Dillon HF: Elements of a paracrine tubular renin-angiotensin system along the entire nephron. Hypertension 1999, 34:1265\u20131274.","journal-title":"Hypertension"},{"key":"87_CR3","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1006\/jmcc.2002.2077","volume":"34","author":"M Bader","year":"2002","unstructured":"Bader M: Role of the local renin-angiotensin system in cardiac damage: a minireview focussing on transgenic animal models. J Mol Cell Cardiol 2002, 34:1455\u20131462.","journal-title":"J Mol Cell Cardiol"},{"key":"87_CR4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/res.90.1.8","volume":"90","author":"M Bader","year":"2002","unstructured":"Bader M, Ganten D: It\u2019s renin in the brain: transgenic animals elucidate the brain renin angiotensin ystem. Circ Res 2002, 90:8\u201310.","journal-title":"Circ Res"},{"key":"87_CR5","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1126\/science.6879184","volume":"221","author":"D Ganten","year":"1983","unstructured":"Ganten D, Hermann K, Bayer C, et al.: Angiotensin synthesis in the brain and increased turnover in hypertensive rats. Science 1983, 221:869\u2013871.","journal-title":"Science"},{"key":"87_CR6","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0196-9781(94)90051-5","volume":"15","author":"PD Senanayake","year":"1994","unstructured":"Senanayake PD, Moriguchi A, Kumagai H, et al.: Increased expression of angiotensin peptides in the brain of transgenic hypertensive rats. Peptides 1994, 15:919\u2013926.","journal-title":"Peptides"},{"key":"87_CR7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0169-328X(93)90155-I","volume":"19","author":"K Shibata","year":"1993","unstructured":"Shibata K, Komatsu C, Misumi Y, Furukawa T: Developmental differences of angiotensinogen mRNA in the preoptic area between spontaneously hypertensive and age-matched Wistar-Kyoto rats. Brain Res Mol Brain Res 1993, 19:115\u2013120.","journal-title":"Brain Res Mol Brain Res"},{"key":"87_CR8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0165-0173(92)90018-H","volume":"17","author":"JW Wright","year":"1992","unstructured":"Wright JW, Harding JW: Regulatory role of brain angiotensins in the control of physiological and behavioral responses. Brain Res Brain Res Rev 1992, 17:227\u2013262.","journal-title":"Brain Res Brain Res Rev"},{"key":"87_CR9","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00004872-199816010-00002","volume":"16","author":"T Unger","year":"1998","unstructured":"Unger T, Culman J, Gohlke P: Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. J Hypertens Suppl 1998, 16:S3-S9.","journal-title":"J Hypertens Suppl"},{"key":"87_CR10","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/01.HYP.2.3.326","volume":"2","author":"RJ Grekin","year":"1980","unstructured":"Grekin RJ, Terris JM, Bohr DF: Electrolyte and hormonal effects of deoxycorticosterone acetate in young pigs. Hypertension 1980, 2:326\u2013332.","journal-title":"Hypertension"},{"key":"87_CR11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1210\/endo-108-1-109","volume":"108","author":"RJ Grekin","year":"1981","unstructured":"Grekin RJ, Sider RS: Aldosterone receptor measurements during changes in dietary sodium. Endocrinology 1981, 108:109\u2013112.","journal-title":"Endocrinology"},{"key":"87_CR12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/0016-6480(84)90231-4","volume":"53","author":"JG Lehoux","year":"1984","unstructured":"Lehoux JG, Bellabarba D, Beaudry C: Corticosteroid receptors in the kidney of chick embryo. III. Nature, properties, and ontogeny of aldosterone receptor. Gen Comp Endocrinol 1984, 53:116\u2013125.","journal-title":"Gen Comp Endocrinol"},{"key":"87_CR13","first-page":"221","volume":"8","author":"N Golestaneh","year":"2002","unstructured":"Golestaneh N, Picaud S, Mirshahi M: The mineralocorticoid receptor in rodent retina: ontogeny and molecular identity. Mol Vis 2002, 8:221\u2013225.","journal-title":"Mol Vis"},{"key":"87_CR14","doi-asserted-by":"crossref","first-page":"C90","DOI":"10.1152\/ajpcell.1978.235.3.C90","volume":"235","author":"N Farman","year":"1978","unstructured":"Farman N, Kusch M, Edelman IS: Aldosterone receptor occupancy and sodium transport in the urinary bladder of Bufo marinus. Am J Physiol 1978, 235:C90-C96.","journal-title":"Am J Physiol"},{"key":"87_CR15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0022-4731(84)90224-3","volume":"20","author":"K Herkner","year":"1984","unstructured":"Herkner K, Pollak A, Swoboda W, Holler B: Explanation of the pseudohypoaldosteronism (PHA)-stress syndrome with an artificial aldosterone receptor model. J Steroid Biochem 1984, 20:317\u2013320.","journal-title":"J Steroid Biochem"},{"key":"87_CR16","doi-asserted-by":"crossref","first-page":"24316","DOI":"10.1016\/S0021-9258(19)51084-5","volume":"269","author":"H Hatakeyama","year":"1994","unstructured":"Hatakeyama H, Miyamori I, Fujita T: Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994, 269:24316\u201324320.","journal-title":"J Biol Chem"},{"key":"87_CR17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00004872-198312000-00012","volume":"1","author":"NR Nichols","year":"1983","unstructured":"Nichols NR, Hall CE, Meyer WJ: Decreased aldosterone receptor affinity in aortic cells from the Fischer 344 rat. J Hypertens 1983, 1:393\u2013397.","journal-title":"J Hypertens"},{"key":"87_CR18","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1210\/endo-98-3-676","volume":"98","author":"NS Anderson III","year":"1976","unstructured":"Anderson NS III, Fanestil DD: Corticoid receptors in rat brain: evidence for an aldosterone receptor. Endocrinology 1976, 98:676\u2013684.","journal-title":"Endocrinology"},{"key":"87_CR19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0022-4731(80)90285-X","volume":"12","author":"M Moguilewsky","year":"1980","unstructured":"Moguilewsky M, Raynaud JP: Evidence for a specific mineralocorticoid receptor in rat pituitary and brain. J Steroid Biochem 1980, 12:309\u2013314.","journal-title":"J Steroid Biochem"},{"key":"87_CR20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000124506","volume":"43","author":"BS McEwen","year":"1986","unstructured":"McEwen BS, Lambdin LT, Rainbow TC, De Nicola AF: Aldosterone effects on salt appetite in adrenalectomized rats. Neuroendocrinology 1986, 43:38\u201343.","journal-title":"Neuroendocrinology"},{"key":"87_CR21","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1126\/science.175.4026.1133","volume":"175","author":"JL Gerlach","year":"1972","unstructured":"Gerlach JL, McEwen BS: Rat brain binds adrenal steroid hormone: radioautography of hippocampus with corticosterone. Science 1972, 175:1133\u20131136.","journal-title":"Science"},{"key":"87_CR22","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1210\/endo-96-3-598","volume":"96","author":"R De Kloet","year":"1975","unstructured":"De Kloet R, Wallach G, McEwen BS: Differences in corticosterone and dexamethasone binding to rat brain and pituitary. Endocrinology 1975, 96:598\u2013609.","journal-title":"Endocrinology"},{"key":"87_CR23","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1007\/BF01963313","volume":"35","author":"MK Birmingham","year":"1979","unstructured":"Birmingham MK, Stumpf WE, Sar M: Nuclear localization of aldosterone in rat brain cells assessed by autoradiography. Experientia 1979, 35:1240\u20131241.","journal-title":"Experientia"},{"key":"87_CR24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1055\/s-2007-1019185","volume":"13","author":"AF Nicola De","year":"1981","unstructured":"De Nicola AF, Tornello S, Weisenberg L, et al.: Uptake and binding of [3H]aldosterone by the anterior pituitary and brain regions in adrenalectomized rats. Horm Metab Res 1981, 13:103\u2013106.","journal-title":"Horm Metab Res"},{"key":"87_CR25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000267990","volume":"29","author":"B Schwartz","year":"1997","unstructured":"Schwartz B, Wysocki A: Mineralocorticoid receptors in the rabbit iris-ciliary body. Ophthalmic Res 1997, 29:42\u201347.","journal-title":"Ophthalmic Res"},{"key":"87_CR26","doi-asserted-by":"crossref","first-page":"21455","DOI":"10.1016\/S0021-9258(20)80556-0","volume":"268","author":"WB Pratt","year":"1993","unstructured":"Pratt WB: The role of heat shock proteins in regulating the function, folding, and trafficking of the glucocorticoid receptor. J Biol Chem 1993, 268:21455\u201321458.","journal-title":"J Biol Chem"},{"key":"87_CR27","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1007\/BF01716720","volume":"60","author":"DD Fanestil","year":"1982","unstructured":"Fanestil DD, Kipnowski J: Molecular action of aldosterone. Klin Wochenschr 1982, 60:1180\u20131185.","journal-title":"Klin Wochenschr"},{"key":"87_CR28","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1210\/endo.142.4.8095","volume":"142","author":"A Bhargava","year":"2001","unstructured":"Bhargava A, Fullerton MJ, Myles K, et al.: The serum- and glucocorticoid-induced kinase is a physiological mediator of aldosterone action. Endocrinology 2001, 142:1587\u20131594.","journal-title":"Endocrinology"},{"key":"87_CR29","first-page":"R197","volume":"276","author":"JP Granger","year":"1999","unstructured":"Granger JP, Kassab S, Novak J, et al.: Role of nitric oxide in modulating renal function and arterial pressure during chronic aldosterone excess. Am J Physiol 1999, 276:R197-R202.","journal-title":"Am J Physiol"},{"key":"87_CR30","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/01.CIR.92.2.175","volume":"92","author":"M Lombes","year":"1995","unstructured":"Lombes M, Alfaidy N, Eugene E, et al.: Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation 1995, 92:175\u2013182.","journal-title":"Circulation"},{"key":"87_CR31","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/0303-7207(95)03559-P","volume":"111","author":"BL Roland","year":"1995","unstructured":"Roland BL, Krozowski ZS, Funder JW: Glucocorticoid receptor, mineralocorticoid receptors, 11 beta-hydroxysteroid dehydrogenase-1 and -2 expression in rat brain and kidney: in situ studies. Mol Cell Endocrinol 1995, 111:R1-R7.","journal-title":"Mol Cell Endocrinol"},{"key":"87_CR32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/01.HYP.29.1.45","volume":"29","author":"Y Takeda","year":"1997","unstructured":"Takeda Y, Miyamori I, Inaba S, et al.: Vascular aldosterone in genetically hypertensive rats. Hypertension 1997, 29:45\u201348.","journal-title":"Hypertension"},{"key":"87_CR33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.25.1.117","volume":"25","author":"M Christ","year":"1995","unstructured":"Christ M, Douwes K, Eisen C, et al.: Rapid effects of aldosterone on sodium transport in vascular smooth muscle cells. Hypertension 1995, 25:117\u2013123.","journal-title":"Hypertension"},{"key":"87_CR34","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1161\/01.HYP.35.5.1099","volume":"35","author":"R Alzamora","year":"2000","unstructured":"Alzamora R, Michea L, Marusic ET: Role of 11beta-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries. Hypertension 2000, 35:1099\u20131104.","journal-title":"Hypertension"},{"key":"87_CR35","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/00313026909071294","volume":"1","author":"JA Inglis","year":"1969","unstructured":"Inglis JA, Halliday JW: Renal damage after subtotal nephrectomy. Pathology 1969, 1:177\u2013183.","journal-title":"Pathology"},{"key":"87_CR36","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/ki.1992.45","volume":"41","author":"ZY Quan","year":"1992","unstructured":"Quan ZY, Walser M, Hill GS: Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int 1992, 41:326\u2013333.","journal-title":"Kidney Int"},{"key":"87_CR37","unstructured":"Akimov I, Kosithyn NS: Influence of unilateral nephrectomy on aldosterone receptors in the remaining kidney in rats. Izv Akad Nauk Ser Biol 2002, 597\u2013600."},{"key":"87_CR38","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1046\/j.1523-1755.2003.00731.x","volume":"63","author":"ME Ullian","year":"2003","unstructured":"Ullian ME, Gantt BJ, Ford AK, et al.: Potential importance of glomerular citrate synthase activity in remnant nephropathy. Kidney Int 2003, 63:156\u2013164.","journal-title":"Kidney Int"},{"key":"87_CR39","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/01.HYP.35.4.875","volume":"35","author":"ME Ullian","year":"2000","unstructured":"Ullian ME, Robinson CJ, Evans CT, et al.: Role of citrate synthase in aldosterone-mediated sodium reabsorption. Hypertension 2000, 35:875\u2013879.","journal-title":"Hypertension"},{"key":"87_CR40","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1681\/ASN.V104814","volume":"10","author":"WR Fitzgibbon","year":"1999","unstructured":"Fitzgibbon WR, Greene EL, Grewal JS, et al.: Resistance to remnant nephropathy in the Wistar-Furth rat. J Am Soc Nephrol 1999, 10:814\u2013821.","journal-title":"J Am Soc Nephrol"},{"key":"87_CR41","first-page":"H1454","volume":"272","author":"ME Ullian","year":"1997","unstructured":"Ullian ME, Islam MM, Robinson CJ, et al.: Resistance to mineralocorticoids in Wistar-Furth rats. Am J Physiol 1997, 272:H1454-H1461.","journal-title":"Am J Physiol"},{"key":"87_CR42","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1210\/endo-109-6-1841","volume":"109","author":"CJ Kenyon","year":"1981","unstructured":"Kenyon CJ, Deconti GA, Cupolo NA, Morris DJ: The role of aldosterone in the development of hypertension in spontaneously hypertensive rats. Endocrinology 1981, 109:1841\u20131845.","journal-title":"Endocrinology"},{"key":"87_CR43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0033-0620(74)90037-1","volume":"17","author":"H Gavras","year":"1974","unstructured":"Gavras H, Brunner HR, Laragh JH: Renin and aldosterone and the pathogenesis of hypertensive vascular damage. Prog Cardiovasc Dis 1974, 17:39\u201349.","journal-title":"Prog Cardiovasc Dis"},{"key":"87_CR44","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1172\/JCI118867","volume":"98","author":"EL Greene","year":"1996","unstructured":"Greene EL, Kren S, Hostetter TH: Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996, 98:1063\u20131068.","journal-title":"J Clin Invest"},{"key":"87_CR45","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","volume":"31","author":"R Rocha","year":"1998","unstructured":"Rocha R, Chander PN, Khanna K, et al.: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998, 31:451\u2013458. Illustrates deleterious role of mineralocorticoids as hormonal mediators of vascular injury and the vascular and end-organ protective effect of spironolactone in an animal model.","journal-title":"Hypertension"},{"key":"87_CR46","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","volume":"33","author":"R Rocha","year":"1999","unstructured":"Rocha R, Chander PN, Zuckerman A, Stier CT Jr: Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999, 33:232\u2013237. Illustrates deleterious role of aldosterone as a mediator of renal injury despite classical RAAS blockade in an animal model.","journal-title":"Hypertension"},{"key":"87_CR47","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","volume":"141","author":"R Rocha","year":"2000","unstructured":"Rocha R, Stier CT Jr, Kifor I, et al.: Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000, 141:3871\u20133878. Offers evidence that aldosterone is a critical mediator of angiotensin II-induced vascular, renal, and cardiac damage in an animal model.","journal-title":"Endocrinology"},{"key":"87_CR48","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/ki.1992.421","volume":"42","author":"J Clore","year":"1992","unstructured":"Clore J, Schoolwerth A, Watlington CO: When is cortisol a mineralocorticoid? Kidney Int 1992, 42:1297\u20131308.","journal-title":"Kidney Int"},{"key":"87_CR49","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/355262a0","volume":"355","author":"RP Lifton","year":"1992","unstructured":"Lifton RP, Dluhy RG, Powers M, et al.: A chimaeric 11 beta-hydroxylase\/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992, 355:262\u2013265.","journal-title":"Nature"},{"key":"87_CR50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1365-2796.1998.00308.x","volume":"244","author":"A Hautanena","year":"1998","unstructured":"Hautanena A, Lankinen L, Kupari M, et al.: Associations between aldosterone synthase gene polymorphism and the adrenocortical function in males. J Intern Med 1998, 244:11\u201318.","journal-title":"J Intern Med"},{"key":"87_CR51","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1097\/00004872-199917110-00009","volume":"17","author":"E Brand","year":"1999","unstructured":"Brand E, Schorr U, Ringel J, et al.: Aldosterone synthase gene (CYP11B2) C-344T polymorphism in Caucasians from the Berlin Salt-Sensitivity Trial (BeSST). J Hypertens 1999, 17:1563\u20131567.","journal-title":"J Hypertens"},{"key":"87_CR52","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0895-7061(99)00176-4","volume":"13","author":"S Patel","year":"2000","unstructured":"Patel S, Steeds R, Channer K, Samani NJ: Analysis of promoter region polymorphism in the aldosterone synthase gene (CYP11B2) as a risk factor for myocardial infarction. Am J Hypertens 2000, 13:134\u2013139.","journal-title":"Am J Hypertens"},{"key":"87_CR53","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/01.HYP.35.3.704","volume":"35","author":"C Hengstenberg","year":"2000","unstructured":"Hengstenberg C, Holmer SR, Mayer B, et al.: Evaluation of the aldosterone synthase (CYP11B2) gene polymorphism in patients with myocardial infarction. Hypertension 2000, 35:704\u2013709.","journal-title":"Hypertension"},{"key":"87_CR54","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1161\/01.CIR.100.22.2213","volume":"100","author":"A Hautanen","year":"1999","unstructured":"Hautanen A, Toivanen P, Manttari M, et al.: Joint effects of an aldosterone synthase (CYP11B2) gene polymorphism and classic risk factors on risk of myocardial infarction. Circulation 1999, 100:2213\u20132218.","journal-title":"Circulation"},{"key":"87_CR55","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1081\/CEH-100107390","volume":"23","author":"M Matsubara","year":"2001","unstructured":"Matsubara M, Omori F, Fujita S, et al.: Haplotypes of aldosterone synthase (CYP11B2) gene in the general population of Japan: the Ohasama study. Clin Exp Hypertens 2001, 23:603\u2013610.","journal-title":"Clin Exp Hypertens"},{"key":"87_CR56","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1097\/00004872-200112000-00010","volume":"19","author":"M Matsubara","year":"2001","unstructured":"Matsubara M, Kikuya M, Ohkubo T, et al.: Aldosterone synthase gene (CYP11B2) C-334T polymorphism, ambulatory blood pressure and nocturnal decline in blood pressure in the general Japanese population: the Ohasama Study. J Hypertens 2001, 19:2179\u20132184.","journal-title":"J Hypertens"},{"key":"87_CR57","first-page":"298","volume":"41","author":"A Chen","year":"2002","unstructured":"Chen A, Zhang W, Tang X, et al.: The relationship of aldosterone synthase gene polymorphism with hypertension and left ventricular hypertrophy. Zhonghua Nei Ke Za Zhi 2002, 41:298\u2013301.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"87_CR58","first-page":"704","volume":"22","author":"AH Chen","year":"2002","unstructured":"Chen AH, Zhang WX, Li ZL, et al.: Association between aldosterone synthase gene polymorphism and hypertrophic cardiomyopathy. Di Yi Jun Yi Da Xue Xue Bao 2002, 22:704\u2013706.","journal-title":"Di Yi Jun Yi Da Xue Xue Bao"},{"key":"87_CR59","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1161\/01.CIR.0000039328.33137.6C","volume":"106","author":"P Lacolley","year":"2002","unstructured":"Lacolley P, Labat C, Pujol A, et al.: Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation 2002, 106:2848\u20132853.","journal-title":"Circulation"},{"key":"87_CR60","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00004872-200301000-00029","volume":"21","author":"MF Neves","year":"2003","unstructured":"Neves MF, Virdis A, Schiffrin EL: Resistance artery mechanics and composition in angiotensin II-infused rats: effects of aldosterone antagonism. J Hypertens 2003, 21:189\u2013198.","journal-title":"J Hypertens"},{"key":"87_CR61","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/0008-6363(96)00053-3","volume":"32","author":"ME Ullian","year":"1996","unstructured":"Ullian ME, Walsh LG, Morinelli TA: Potentiation of angiotensin II action by corticosteroids in vascular tissue. Cardiovasc Res 1996, 32:266\u2013273.","journal-title":"Cardiovasc Res"},{"key":"87_CR62","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1210\/en.2002-220120","volume":"143","author":"R Rocha","year":"2002","unstructured":"Rocha R, Martin-Berger CL, Yang P, et al.: Selective aldosterone blockade prevents angiotensin II\/salt-induced vascular inflammation in the rat heart. Endocrinology 2002, 143:4828\u20134836.","journal-title":"Endocrinology"},{"key":"87_CR63","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1161\/01.CIR.0000039104.56479.42","volume":"106","author":"G Suzuki","year":"2002","unstructured":"Suzuki G, Morita H, Mishima T, et al.: Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002, 106:2967\u20132972.","journal-title":"Circulation"},{"key":"87_CR64","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0021-9150(02)00363-5","volume":"166","author":"P Romagni","year":"2003","unstructured":"Romagni P, Rossi F, Guerrini L, et al.: Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 2003, 166:345\u2013349.","journal-title":"Atherosclerosis"},{"key":"87_CR65","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709\u2013717. First large-scale study in human subjects to prove that aldosterone blockade with spironolactone improves survival and is cardioprotective in patients with CHF.","journal-title":"N Engl J Med"},{"key":"87_CR66","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309\u20131321. First large-scale study in human subjects to prove that eplerenone, the new selective aldosterone receptor antagonist, improves survival and is cardioprotective in patients with CHF.","journal-title":"N Engl J Med"},{"issue":"11","key":"87_CR67","first-page":"S30","volume":"10","author":"R Ardaillou","year":"1999","unstructured":"Ardaillou R: Angiotensin II receptors. J Am Soc Nephrol 1999, 10(11):S30-S39.","journal-title":"J Am Soc Nephrol"},{"key":"87_CR68","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1291\/hypres.23.25","volume":"23","author":"A Sato","year":"2000","unstructured":"Sato A, Suzuki Y, Shibata H, Saruta T: Plasma aldosterone concentrations are not related to the degree of angiotensinconverting enzyme inhibition in essential hypertensive patients. Hypertens Res 2000, 23:25\u201331. Introduces the concept of aldosterone synthesis escape despite classical RAAS blockade in human subjects by proving that plasma aldosterone concentrations tend to increase with the duration of ACE inhibitor treatment.","journal-title":"Hypertens Res"},{"key":"87_CR69","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","volume":"41","author":"A Sato","year":"2003","unstructured":"Sato A, Hayashi K, Naruse M, Saruta T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003, 41:64\u201368. First study in the literature to suggest that aldosterone blockade is renoprotective in patients with early diabetic nephropathy who show aldosterone escape during ACE inhibitor treatment and who no longer show maximal antiproteinuric effects of ACE inhibition.","journal-title":"Hypertension"},{"key":"87_CR70","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/147323000102900103","volume":"29","author":"A Sato","year":"2001","unstructured":"Sato A, Saruta T: Aldosterone escape during angiotensinconverting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001, 29:13\u201321. Introduces the concept that aldosterone synthesis escape may reverse the beneficial effects of an ACE inhibitor on left ventricular hypertrophy.","journal-title":"J Int Med Res"},{"key":"87_CR71","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/S0735-1097(01)01237-2","volume":"37","author":"M Cicoira","year":"2001","unstructured":"Cicoira M, Zanolla L, Rossi A, et al.: Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 2001, 37:1808\u20131812.","journal-title":"J Am Coll Cardiol"},{"key":"87_CR72","doi-asserted-by":"crossref","unstructured":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987, 316:1429\u20131435.","DOI":"10.1056\/NEJM198706043162301"},{"key":"87_CR73","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0002-9149(01)02261-5","volume":"89","author":"M Cicoira","year":"2002","unstructured":"Cicoira M, Zanolla L, Franceschini L, et al.: Relation of aldosterone \"escape\" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2002, 89:403\u2013407.","journal-title":"Am J Cardiol"},{"key":"87_CR74","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/ajkd.2001.22069","volume":"37","author":"T Shiigai","year":"2001","unstructured":"Shiigai T, Shichiri M: Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease. Am J Kidney Dis 2001, 37:477\u2013483.","journal-title":"Am J Kidney Dis"},{"key":"87_CR75","first-page":"293","volume":"55","author":"S Li","year":"2001","unstructured":"Li S, Wu P, Zhong S, et al.: Effects of long-term enalapril and losartan therapy of hypertension on cardiovascular aldosterone. Horm Res 2001, 55:293\u2013297.","journal-title":"Horm Res"},{"key":"87_CR76","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/BF03344039","volume":"25","author":"JC Xiu","year":"2002","unstructured":"Xiu JC, Wu P, Xu JP, et al.: Effects of long-term enalapril and losartan therapy of heart failure on cardiovascular aldosterone. J Endocrinol Invest 2002, 25:463\u2013468.","journal-title":"J Endocrinol Invest"},{"key":"87_CR77","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G: A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667\u20131675.","journal-title":"N Engl J Med"},{"key":"87_CR78","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0735-1097(02)02063-6","volume":"40","author":"M Wong","year":"2002","unstructured":"Wong M, Staszewsky L, Latini R, et al.: Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002, 40:970\u2013975.","journal-title":"J Am Coll Cardiol"},{"key":"87_CR79","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1046\/j.1523-1755.2001.00745.x","volume":"59","author":"R Agarwal","year":"2001","unstructured":"Agarwal R: Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 2001, 59:2282\u20132289.","journal-title":"Kidney Int"},{"key":"87_CR80","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","volume":"102","author":"F Zannad","year":"2000","unstructured":"Zannad F, Alla F, Dousset B, et al.: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000, 102:2700\u20132706.","journal-title":"Circulation"},{"key":"87_CR81","first-page":"1279","volume":"43","author":"S Kasama","year":"2002","unstructured":"Kasama S, Toyama T, Kumakura H, et al.: Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med 2002, 43:1279\u20131285.","journal-title":"J Nucl Med"},{"key":"87_CR82","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0735-1097(02)01965-4","volume":"40","author":"M Cicoira","year":"2002","unstructured":"Cicoira M, Zanolla L, Rossi A, et al.: Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 2002, 40:304\u2013310.","journal-title":"J Am Coll Cardiol"},{"key":"87_CR83","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0735-1097(01)01116-0","volume":"37","author":"T Tsutamoto","year":"2001","unstructured":"Tsutamoto T, Wada A, Maeda K, et al.: Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001, 37:1228\u20131233.","journal-title":"J Am Coll Cardiol"},{"key":"87_CR84","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1011119003788","volume":"15","author":"B Pitt","year":"2001","unstructured":"Pitt B, Williams G, Remme W, et al.: The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001, 15:79\u201387.","journal-title":"Cardiovasc Drugs Ther"},{"key":"87_CR85","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1067\/mhj.2002.120775","volume":"143","author":"JA Spertus","year":"2002","unstructured":"Spertus JA, Tooley J, Jones P, et al.: Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone\u2019s neuro-Hormonal Efficacy and SUrvival Study). Am Heart J 2002, 143:636\u2013642.","journal-title":"Am Heart J"},{"key":"87_CR86","doi-asserted-by":"crossref","first-page":"24A","DOI":"10.1016\/S0895-7061(02)02333-6","volume":"15","author":"M Epstein","year":"2002","unstructured":"Epstein M, Buckalew V, Martinez F, et al.: Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone\/enalapril combination in diabetic hypertensives with microalbuminuria [abstract]. Am J Hypertens 2002, 15:24A.","journal-title":"Am J Hypertens"},{"key":"87_CR87","first-page":"650","volume":"240","author":"M Gasparo de","year":"1987","unstructured":"de Gasparo M, Joss U, Ramjoue HP, et al.: Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987, 240:650\u2013656.","journal-title":"J Pharmacol Exp Ther"},{"key":"87_CR88","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2125.1989.tb03421.x","volume":"27","author":"M Gasparo de","year":"1989","unstructured":"de Gasparo M, Cumin F, Nussberger J, et al.: Pharmacological investigations of a new renin inhibitor in normal sodiumunrestricted volunteers. Br J Clin Pharmacol 1989, 27:587\u2013596.","journal-title":"Br J Clin Pharmacol"},{"key":"87_CR89","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1046\/j.1523-1755.2000.00983.x","volume":"57","author":"JA Delyani","year":"2000","unstructured":"Delyani JA: Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int 2000, 57:1408\u20131411.","journal-title":"Kidney Int"},{"key":"87_CR90","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger MH, Roniker B, Krause SL, Weiss RJ: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002, 15:709\u2013716.","journal-title":"Am J Hypertens"},{"key":"87_CR91","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","volume":"40","author":"H Krum","year":"2002","unstructured":"Krum H, Nolly H, Workman D, et al.: Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002, 40:117\u2013123. Illustrates the antihypertensive effects of eplerenone and that eplerenone may be useful add-on therapy in hypertensive patients inadequately controlled on an ACE inhibitor or ARB alone.","journal-title":"Hypertension"},{"key":"87_CR92","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1053\/euhj.2000.2365","volume":"22","author":"H Krum","year":"2001","unstructured":"Krum H, Nolly H, Roniker B, et al.: Coadministration of eplerenone with an angiotensin-converting enzyme inhibitor or an angiotensin II blocker in patients with mild to moderate hypertension (supplement). Eur Heart J 2001, 22:612.","journal-title":"Eur Heart J"},{"key":"87_CR93","first-page":"431","volume":"17","author":"HN Ibrahim","year":"1997","unstructured":"Ibrahim HN, Rosenberg ME, Hostetter TH: Role of the reninangiotensin-aldosterone system in the progression of renal disease: a critical review. Semin Nephrol 1997, 17:431\u2013440.","journal-title":"Semin Nephrol"},{"key":"87_CR94","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ki.1997.2","volume":"51","author":"G Remuzzi","year":"1997","unstructured":"Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression. Kidney Int 1997, 51:2\u201315.","journal-title":"Kidney Int"},{"key":"87_CR95","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2169\/internalmedicine.40.573","volume":"40","author":"M Epstein","year":"2001","unstructured":"Epstein M: Aldosterone as a mediator of progressive renal dysfunction: evolving perspectives. Intern Med 2001, 40:573\u2013583.","journal-title":"Intern Med"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-003-0087-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-003-0087-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-003-0087-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T05:10:11Z","timestamp":1628917811000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-003-0087-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10]]},"references-count":95,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,10]]}},"alternative-id":["87"],"URL":"https:\/\/doi.org\/10.1007\/s11906-003-0087-9","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10]]}}}